All News
Guselkumab a Hit in Phase III for PsA
The monoclonal antibody guselkumab (Tremfya), which binds the interleukin (IL)-23 p19 subunit, was effective for psoriatic arthritis in two large clinical trials, providing comprehensive benefits for this heterogeneous disorder, investigators reported in The Lancet.
Read Article
RheumNow Podcast – The Beginning of Something Else (4.10.20)
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com
Read Article
TNR - Grand Rounds: Safety of Biologics & New Agents
On Tuesday, April 7th, RheumNow hosted its first Tuesday Nite Rheumatology webinar - kicking off a two-month series of Rheumatology Grand Rounds lectures. The first session featured Jack Cush, MD (UT Southwestern) who lectured on "The Safety of Biologics and Newer Agents".
Read Article
NICE Guidelines on Managing Rheumatologic Conditions During COVID-19 Pandemic
On April 3rd, the National Institute for Health and Care Excellence (NICE) in the UK, published a rapid guideline for managing children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection.
Read Article
RheumNow Podcast – Pandemic Numbers (4.3.20)
Dr. Jack Cush reviews the news on COVID-19 and FDA actions this past week. Be sure to check out:
Read Article
CDC: Impact of Underlying Health Conditions Among COVID-19 Patients
The March 31 release of the Morbidity and Mortality Weekly Report (MMWR) reviews the impact of several key comorbidities, most commonly diabetes mellitus, chronic lung disease, and cardiovascular disease, as cofactors leading to worse outcomes with COVID-19 infections. Below are e
Read Article
RheumNow Podcast – New World Order (3.27.20)
Dr. Jack Cush reviews the news and COVID developments from this past week.
Read Article
ACR Infusion Guidance During COVID-19 Crisis
The American College of Rheumatology (ACR) has published a guidance document on infusions and office based therapies.
Read Article
Dr. Artie Kavanaugh - Don't Stop!
Drs. Cush and Kavanaugh discuss the downside of stopping hydroxychloroquine, DMARDs and biologics in lupus, RA and pregnancy.
Read Article
Global Rheumatology Alliance Registry Will Study COVID-19
In the midst of a global pandemic of the 2019 Novel coronavirus acute respiratory disease (COVID-19), a small handful of Rheumatologists gathered on social media to collectively grapple with the impact of this virus on vulnerable populations with rheumatic disease.
Infusions in the Time of Coronavirus
As they say, necessity is the mother of invention. After years of bemoaning the challenges of telemedicine, our rheumatology clinic transition entirely to a remote clinic in the space of a week.
Read Article
COVID-19 Rheumatology News
With the COVID-19 pandemic dynamically changing, we have provided several news items germane to the Rheumatologist.
Read Article
The COVID-19 Global Rheumatology Registry
As the highly virulent SARS-CoV-2 spreads over the world, uncertainty and fear for our patients with rheumatic diseases mount.
Read Article
Rheumatic Disease Drugs and COVID-19
We are in the early stages of trying to limit the morbid and mortal consequences of the corona virus pandemic of 2020. Not surprisingly, the recommendations designed to limit exposure and damage continually highlight the fact that the elderly and immunosuppressed may be amongst the most severely affected should they become infected with this virus.
This has led to a great deal of uncertainty by patients and providers about how rheumatic diseases and their treatments need to be specifically addressed.
RheumNow Podcast- Corona Increases RA Risk (3.13.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Earlier Anakinra Initiation Warranted in Still's Disease
An Italian study examined the outcomes in adult onset Still's disease (AOSD) based on whether they received early or delayed treatment with anakinra (ANK).
A total of 141 AOSD patients were retrospectively studied.
Read Article
Switching Biologics in JIA
While there are numerous agents approved for use in juvenile idiopathic arthritis, little is know about actual use biological disease-modifying antirheumatic drug (DMARD) use or switching in the biologic era. A cohort comparison study has shown that after an unsuccessful trial of a first biologic, changing to a second TNFi is as effective as switching to a non-TNFi biologic.
Read Article
EMA Final Recommendations on VTE Risk with Tofacitinib
On 14 November 2019 the European Medicines Agency (EMA) concluded that Xeljanz (tofacitinib) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk. These recommendations have been formally published and are intended for EU nation
Read Article
Need for Disruptive Innovation in Rheumatology
A full-read, novel Viewpoint article published in the Annals of Rheumatic Disease (Huizinga TWJ, et al) spotlights a recent international meeting of big thinkers, scientific collaborators and industry dedicated to innovation in rheumatology.
Read Article
